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Introduction
HER-2 is one of four Erb B family-type I receptor tyrosine
kinases and is the preferred dimerisation partner for the
epidermal growth factor receptor [1,2]. The Erb B recep-
tors are important in normal development and in human
cancer. HER-2, independent of its own ligand, activates
other Erb B receptors to increase their ligand affinity and
to amplify biological responses. HER-2 plays a key role in
activating cytoplasmic signalling through the phos-
phatidylinositol-3 kinase (PI-3K)/protein kinase B (Akt) and
mitogen-activated protein kinase pathways to influence
transcription of nuclear genes [2–4]. Activation of
PI-3K/Akt is involved in cell proliferation and confers resis-
tance to apoptosis [5,6]. Breast cancer is associated with
Akt = protein kinase B; CDK = cyclin-dependent kinases; ELISA = enzyme-linked immunosorbent assay; ER = oestrogen receptor; IDS = intensity
distribution score; NPI = Nottingham Prognostic Index; OS = overall survival; PI-3K = phosphatidylinositol-3 kinase; RFS = relapse-free survival.
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Abstract
Background HER-2 (c-erbB2/Neu) predicts the prognosis of
and may influence treatment responses in breast cancer.
HER-2 activity induces the cytoplasmic location of p21WAFI/CIPI
in cell culture, accompanied by resistance to apoptosis.
p21WAFI/CIPI is a cyclin-dependent kinase inhibitor activated by
p53 to produce cell cycle arrest in association with nuclear
localisation of p21WAFI/CIPI. We previously showed that higher
levels of cytoplasmic p21WAFI/CIPI in breast cancers predicted
reduced survival at 5 years. The present study examined HER-2
and p21WAFI/CIPI expression in a series of breast cancers with
up to 9 years of follow-up, to evaluate whether in vitro findings
were related to clinical data and the effect on outcome.
Methods The CB11 anti-HER2 monoclonal antibody and the
DAKO Envision Plus system were used to evaluate HER-2
expression in 73 patients. p21WAFI/CIPI staining was performed
as described previously using the mouse monoclonal antibody
Ab-1 (Calbiochem, Cambridge, MA, USA).
Results HER-2 was evaluable in 67 patients and was
expressed in 19% of cases, predicting reduced overall survival
(P=0.02) and reduced relapse-free survival (P=0.004; Cox
regression model). HER-2-positive tumours showed
proportionately higher cytoplasmic p21WAFI/CIPI staining using
an intensity distribution score (median, 95) compared with
HER-2-negative cancers (median, 47) (P=0.005). There was a
much weaker association between nuclear p21WAFI/CIPI and
HER-2 expression (P=0.05), suggesting an inverse
relationship between nuclear p21WAF1/CIP1 and HER-2.
Conclusion This study highlights a new pathway by which
HER-2 may modify cancer behaviour. HER-2 as a predictor of
poor prognosis may partly relate to its ability to influence the
relocalisation of p21WAFI/CIPI from the nucleus to the cytoplasm,
resulting in a loss of p21WAFI/CIPI tumour suppressor functions.
Cytoplasmic p21WAFI/CIPI may be a surrogate marker of
functional HER-2 in vivo.
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deregulated expression of HER-2, detectable as HER-2
amplification or protein overexpression identified in
10–40% of tumours [7]. HER-2 expression is indicative of
poor prognosis and may predict tumour responses to
hormone therapy and chemotherapy.
Cell cycle progression is regulated by cyclin-dependent
kinases (CDKs) associated with cyclin proteins.
p21WAF1/CIP1, a downstream target of p53, is a CDK
inhibitor that re-enforces p53-mediated G1 and G2 arrest
following genotoxic insults, to facilitate DNA repair [8–11].
The integrity of G1 and G2 checkpoints requires the
nuclear localisation of p21WAF1/CIP1 [11,12]. Recent evi-
dence including subcellular fractionation suggests that
p21WAF1/CIP1 can localise in the cytoplasm in cancer
tissues and cell lines, where it inhibits apoptosis by
binding and inhibiting the apoptosis signal-regulating
kinase 1 [13–17]. Such an anti-apoptotic function in
breast cancers could underlie the association between
cytoplasmic p21WAF1/CIP1 and poor prognosis [17].
Upregulation of p21WAF1/CIP1 occurs through PI-3K/Akt
signalling, and may involve insulin-like growth factors,
p53-dependent pathways or HER-2 expression [18–20].
A HER-2-overexpressing breast cancer cell line transcrip-
tionally upregulates p21WAF1/CIP1 and has been shown to
produce its cytoplasmic localisation through a mechanism
whereby Akt binds and phosphorylates p21WAF1/CIP1 in its
nuclear localisation signal [21]. In vivo HER-2 expression
may involve changes in the subcellular localisation of
p21WAF1/CIP1 to influence the outcome in breast cancer.
We previously found that breast cancers with higher levels
of cytoplasmic p21WAF1/CIP1 predicted reduced overall
survival (OS) and relapse-free survival (RFS), with correla-
tion between cytoplasmic p21WAF1/CIP1 and p53 expres-
sion on immunohistochemistry [17]. Recent in vitro
findings demonstrated a direct influence of HER-2 on
cytoplasmic p21WAF1/CIP1. This influence prompted us to
investigate HER-2 expression in a retrospective series of
breast cancers with p21WAF1/CIP1 staining by immunohis-
tochemistry and a further 4 years of patient follow-up [21].
We are not aware of any other study to date examining
subcellular p21WAF1/CIP1 expression in relation to HER-2
immunoreactivity.
Patients and methods
Patients
The study included 73 patients aged 32–80 years
(median, 55 years) with primary infiltrating carcinoma diag-
nosed between 1989 and 1992 at the John Radcliffe Hos-
pital. The eligibility criteria were histological diagnosis of
breast carcinoma, level one or complete axillary lymph
node dissection, no distant metastases and unilateral
tumour. Forty-nine (67%) cases were node-negative and
24 (33%) cases were node-positive (N1-mobile ipsilateral
or N2-fixed ipsilateral).
Clinicopathological subgroups were analysed according
to the Nottingham Prognostic Index (NPI). They were
divided into good, moderate and poor prognostic groups
as previously described, with a modification that included
no assessment of the internal mammary lymph nodes
[22,23]. Seventeen nongraded nonductal cancers were
not included in the NPI groups.
Adjuvant treatment groups comprised tamoxifen (16 node-
negative patients, 14 node-positive patients), cyclophos-
phamide/methotrexate/5-fluorouracil (six node-negative
patients, six node-positive patients), and both tamoxifen
plus cyclophosphamide/methotrexate/5-fluorouracil (two
node-negative patients, four node-positive patients).
Twenty-five node-negative women received no adjuvant
treatment.
The median duration of follow-up was 110 months (range,
46–144 months) among patients who were alive at the
date of their last visit. Tumour samples were collected
shortly after surgery and were fixed in buffered formalin for
24–48 hours at room temperature. Tumours were classi-
fied according to Azzopardi [24]. Invasive ductal carcino-
mas were graded by the modified Bloom’s grading system
described by Elston and Ellis [25]. The oestrogen recep-
tor (ER) status was determined using an ELISA assay
(Abbott-ERICA; Abbott Laboratories, Maidenhead, UK).
Tumours were classified as ER-positive if oestradiol
binding exceeded 10fmol/mg cytosolic protein.
Immunohistochemistry
HER-2 immunostaining was performed using the mouse
monoclonal anti-HER-2 antibody (RTU-CB11) (NovaCastra/
Vector, Newcastle upon Tyne, UK), and the DAKO Envi-
sion Plus HRP system (K4006; DAKO, Ely, Cam-
bridgeshire, UK). Formalin-fixed paraffin sections of breast
cancer tissue were baked, dewaxed and rehydrated prior
to a peroxidase block (0.1%, v/v hydrogen peroxide) and
an incubation in 10% v/v normal goat serum. The primary
antibody and horseradish peroxide-labelled polymer were
used as per the DAKO Envision kit, followed by
3,3-diaminobenzidine and counterstaining with haema-
toxylin before mounting.
HER-2 expression was scored according to the degree
and the proportion of membrane staining [26]. HER-2
expression was negative for a score of 0 or 1+. A score of
0 was defined as no staining or membrane staining in less
than 10% of tumour cells. A score of 1+ comprised faint
or partly-stained membranes in more than 10% of tumour
tissue. Overexpression of c-erbB2 was scored as 2+,
defined as weak to moderate complete membrane stain-
ing in more than 10% of tumour cells. A score of 3+ was
interpreted as strong, complete membrane staining in
more than 10% of tumour. This was analysed in the
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p21WAF1/CIP1 immunoreactivity was evaluated using the
mouse monoclonal antibody Ab-1 (Calbiochem, Cam-
bridge, MA, USA) at 0.5µg/ml. Biotinylated goat anti-
mouse IgG (DAKO, Glostrup, Denmark) secondary
antibody was used at 15µg/ml. The Strept ABC Duet kit
(DAKO, Denmark) was used for p21WAF1/CIP detection
[17]. Immunostaining was assessed using a Laborlux
microscope (Leitz, Wetzlar, Germany) at 400× overall
magnification with a field diameter of 0.46mm.
p21WAF1/CIP1 immunoreactivity was assessed as the
degree of staining intensity and the proportion of cells with
p21WAF1/CIP1 in the nucleus and in the cytoplasm, which
was graded semiquantitatively to produce an intensity dis-
tribution score (IDS) for each localisation [17]. Calculation
of the IDS was performed as follows: IDS (maximum score
300) = 1× per cent of weakly stained cells + 2× per cent
of moderately stained cells + 3× per cent of strongly
stained cells. Average IDS values were determined by
examination of 10 fields [17].
Statistical analysis
The association between HER-2 and patient characteris-
tics was assessed using the Mann–Witney test for contin-
uous variables and the chi-squared test for categorical
factors. The relationship between HER-2 and the subcellu-
lar localisation of p21WAF1/CIP1 was analysed using the
Mann–Witney U test, with the p21WAF1/CIP1 IDS used as a
continuous variable. Analyses of survival data were per-
formed using the log-rank test and the Cox regression
model, with survival curves computed using the
Kaplain–Meier method.
For both HER-2 and p21WAF1/CIP1 markers univariate and
multivariate analyses were performed, the latter adjusting
for the NPI score and the treatment received (tamoxifen/
chemotherapy/no treatment). As the NPI is based on
nodal involvement, on tumour size and on grade, patients
with histologies for whom grade is undefined (‘other’
cancers) were excluded from the regression analyses.
Thirteen patients (all either ductal carcinoma, lobular carci-
noma or mixed histology) had no grade information
recorded in the data and one patient had no tumour size
recorded. These patients were included in the analysis
using multiple imputation methods [27] to estimate the
missing values.
The hazard ratios were derived from the average effect
across 10 augmented datasets, with the confidence inter-
vals and significance tests taking into account the uncer-
tainty of the imputations. The multiple imputation was
performed by the MICE library within the S-Plus 2000
Guide to Statistics Volumes 1 and 2 (MathSoft, Seattle,
WA, USA), and all other analyses were performed using
the STATA version 7 software (STATA Corporation,
College Station, TX, USA) [28].
Results
HER-2 expression and association with
clinicopathologic factors
HER-2 immunoreactivity was evaluable in 67 (92%)
cases, and scored positively in 13 (19%) cases (Fig.1)
using scoring of 2+ and 3+ as indicative of HER-2 protein
overexpression. Tumours with HER-2 scores of 0 or 1+
were assessed as negative. HER-2 expression was
analysed in relation to clinicopathologic criteria (Table 1),
with a significant association of HER-2 positivity with
young age (≤50 years) (P=0.03) and with ER-negative
(≤10fmol/mg) tumours (P=0.05).
Association of HER-2 with subcellular localisation of
p21WAF1/CIP1
p21WAF1/CIP1 expression measured as an IDS was
analysed in the nucleus and in the cytoplasm in relation to
HER-2 expression (Fig.1). Nuclear p21WAFI/CIP1 was
higher in HER-2-negative tumours with a median IDS of
7.3 (range, 0–88.5), compared with a median IDS of 2.3
(range, 0–37.5) in HER-2-positive breast cancers
(P=0.05) (Fig.2). Cytoplasmic p21WAF1/CIP1 staining was
significantly higher in HER-2-positive cancers with a
median IDS of 95 (range, 12.5–154.5; P=0.005), com-
Table 1
Clinicopathological variables according to c-erbB2 status
HER-2-negative HER-2-positive P Overall
Total 54 13 67
Oestrogen receptor status
≤10fmol/mg 25 10 0.05* 35
>10fmol/mg 29 3 32
Node status
Negative 36 8 0.73 44
Positive 18 5 23
Histologic grade
Grade I 4 0 0.48 4
Grade II 17 5 22
Grade III 22 7 29
‘Other’ 11 1 12
Nottingham Prognostic Index
GPG score ≤3.4 4 1 0.61 6
MPG score 3.4–5.4 28 8 40
PPG score >5.4 7 3 10
Age
<50years 19 8 28
≥50years 35 5 39
Median (range) 56 (32–80) 46 (37–67) 0.03* 55 (32–80)
Tumour size
≤2cm 15 4 19
>2cm 39 9 48
Median (range) 2.5 (1–5.5) 2.6 (1–5.3) 0.76 2.5 (1–5.5)
GPG, good prognostic group; MPG, moderate prognostic group;
PPG, poor prognostic group.
*Relationship reached significance (P≤0.05).pared with HER-2-negative tumours with a median IDS of
47 (range, 0–134.6) (Fig.2).
These results suggest that HER-2-positive tumours
showed an increase in cytoplasmic p21WAF1/CIP1 of
50 IDS units, compared with a decrease of 5 IDS units for
nuclear p21WAF1/CIP1. Despite proportionately lower
nuclear p21WAF1/CIP1 levels on IDS, the HER-2-associated
increase is far greater in terms of cytoplasmic immuno-
reactivity. This suggests that the association between
cytoplasmic p21WAF1/CIP1 and HER-2 positivity is stronger
than for nuclear p21WAF1/CIP1.
Relationship of clinicopathological factors to prognosis
and the predictive potential of HER-2 and p21WAF1/CIP1
expression
At 9 years, disease relapses were seen in 33 patients (22
of 48 node-negative patients and 11 of 25 node-positive
patients); 30 women died from breast carcinoma. The
9-year RFS and OS were 52% and 61%, respectively.
Poor prognostic factors such as the presence of lymph
node metastases, high tumour grade, large tumour size
and negative ER status were all associated with a lower
percentage of patients remaining disease-free (RFS) and
alive (OS) at 9 years (data not shown). The 5-year OS of
the NPI subgroups were 67% (95% confidence interval,
19–95%) for the good prognostic group, 78% (95% con-
fidence interval, 61–88%) for the moderate prognostic
group and 40% (95% confidence interval, 12–67%) for
the poor prognostic group, respectively.
Univariate and multivariate analyses were used to investi-
gate possible relationships between patient survival data
and HER-2 expression, and the subcellular distribution of
p21WAF1/CIP1 (Table 2). Univariate analysis showed that
HER-2 was significantly associated with a decreased OS
(P=0.05) and a decreased RFS (P=0.02) (Table 2 and
Fig.3). Cytoplasmic p21WAF1/CIP was associated with a
decreased OS and a decreased RFS on univariate analy-
sis (P=0.03) (Table 2). The multivariate analysis was
adjusted for the NPI and treatment groups (no treatment,
tamoxifen, other) (Table 2). Multivariate analysis demon-
strated the independent prognostic significance of cyto-
plasmic p21WAF1/CIP and HER-2 in relation to OS and
RFS, while nuclear p21WAF1/CIP was not a prognosticator
in this study.
Discussion
HER-2 enhances cancer cell growth, and a number of in
vitro studies have highlighted mechanisms to explain its
Available online http://breast-cancer-research.com/content/5/6/R242
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Figure 1
Examples of HER-2 and p21WAF1/CIP1 immunoreactivity in infiltrating ductal carcinoma of the breast. Immunostaining was performed as described in
Materials and methods, and nuclei were counterstained with haematoxylin. (a) A tumour showing HER-2 overexpression, with (b) a concomitant
predominance of cytoplasmic p21WAF1/CIP1 staining and minimal or no nuclear p21WAF1/CIP1 expression. (c) A HER-2-negative tumour, with (d) a
predominance of nuclear p21WAF1/CIP1 expression compared with cytoplasmic p21WAF1/CIP1, which was proportionately less on intensity
distribution scoring in 10 fields. Insets in panels (b) and (d) show higher-power views of the same fields. Magnification ×3–4.oncogenic potential [18,19,21,29–31]. The relevance of
these mechanisms in vivo requires further investigation.
Analysis of HER-2 expression in breast cancer is impor-
tant in the interpretation of patient prognosis and treat-
ment response. In this study, the immunohistochemical
detection of HER-2 was in keeping with the reported fre-
quency of protein expression in breast cancers. Despite
controversy surrounding the relative value of immunohisto-
chemistry and fluorescence in situ hybridisation to evalu-
ate HER-2 overexpression, a recent study has shown
good concordance for both tests [32].
HER-2 positivity independently predicted prognosis in this
group of breast cancers, and was associated with lack of
ER expression (Tables 1 and 2, and Fig.3). Mechanisms
underpinning the association of HER-2 with ER-negative
tumours need to be determined, with in vitro evidence
indicating a negative regulation of HER2 transcription by
steroid hormones [29]. Clinical relevance of these path-
ways may underlie hormone resistance in HER-2-express-
ing breast cancers [30].
HER-2 potentiates ligand-induced intracellular signalling
by targeting the Akt oncoprotein that mediates cytoplas-
mic PI-3K signalling [21]. Through this mechanism, HER-2
and Akt have been shown to block apoptosis in vitro by
regulating p21WAF1/CIP1 and by enhancing p53 degrada-
tion [21,31]. HER-2 increases p21WAF1/CIP1 expression to
inhibit the mitotic CDC2 kinase and to block Taxol-
induced apoptosis [19]. Through an alternative anti-apop-
totic pathway, HER-2 induces cytoplasmic p21WAF1/CIP
[21]. Immunofluorescence and subcellular fractionation
Breast Cancer Research    Vol 5 No 6 Winters et al.
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Figure 2
Relationship between HER-2 and p21WAF1/CIP1 localisation. Scatter
plots according to HER-2 status and the subcellular localisation of
p21WAF1/CIP1 measured as an intensity distribution score (IDS). HER-2
staining was analysed as described in Materials and methods. 
(a) Distribution of nuclear p21WAF1/CIP1 IDS and medians according to
HER-2-negative and HER-2-positive breast cancers, with patient
numbers shown. (b) Cytoplasmic p21WAF1/CIP1 IDS and medians
according to HER-2 status, and numbers of patients. Of the
67 patients, nuclear p21WAF1/CIP1 was not evaluable in four patients, or
in the cytoplasm in six cases. P values indicate significance.
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Table 2
Relationships between HER-2 and p21WAF1/CIP1 localisation and overall survival/relapse-free survival
Univariate analysis Multivariate analysis
Hazard 95% Hazard 95%
Number ratio per 10 IDS confidence ratio per 10 IDS confidence
of patients units for p21 interval P units for p21 interval P
Overall survival
p21
p21 nucleus 64 0.96 0.77, 1.19 0.70 0.96 0.75, 1.22 0.73
p21 cytoplasm 63 1.12* 1.01, 1.25 0.03* 1.15* 1.03, 1.28 0.01*
HER-2 (2+/3+ versus 0/1+) 63 2.26* 1.00, 5.27 0.05* 3.14* 1.15, 8.64 0.03*
Relapse-free survival
p21
p21 nucleus 64 1.01 0.84, 1.22 0.89 1.03 0.84, 1.25 0.80
p21 cytoplasm 63 1.12* 1.01, 1.24 0.03* 1.15* 1.02, 1.28 0.02*
HER-2 (2+/3+ versus 0/1+) 63 2.60* 1.19, 5.71 0.02* 4.08* 1.60, 10.39 0.003*
Hazard ratios, confidence intervals and P values are given for the results of both the univariate analyses and the multivariate analyses. For univariate
and multivariate analyses, the hazard ratio is given for nuclear and cytoplasmic p21WAF1/CIP1 per 10 unit increase in intensity distribution score
(IDS), along with the 95% confidence interval. The hazard ratio and confidence interval for HER-2 relates to 2+/3+ versus 0/1+. Patients with
ductal, lobular or ‘mixed’ cancer were included where the marker data was available. The multivariate analysis is adjusted for the Nottingham
Prognostic Index (NPI) (nodes, grade and size) and for treatment (tamoxifen/chemotherapy/no treatment), with the NPI based on imputed grades
and tumour sizes where the relevant data were missing as described in the statistical methods.
*Relationship reached significance (P<0.05).have previously demonstrated cytoplasmic p21WAF1/CIP1 in
cell lines characterised by transformation, anchorage inde-
pendence and anti-apoptosis [13–16].
Predominant cytoplasmic p21WAF1/CIP1 has been detected
immunohistochemically in breast tumours and in ovarian
tumours [15,17]. Previous studies of breast carcinoma
have reported the exclusive nuclear localisation of
p21WAF1/CIP1 [33–35]. In our study, cytoplasmic
p21WAF1/CIP1 staining was evident as previously reported
[33,36,37] and was based on the method of microwave
antigen retrieval (Fig.1b) using an alkaline buffer (Tris-
buffered saline/EDTA, pH9.0), rather than the acidic
citrate buffer (pH6.0) [17,34,35]. This series of breast
cancers shows an important association between HER-2
and increased cytoplasmic p21WAF1/CIP1 to substantiate in
vitro findings (Figs1 and 2) [21]. An inverse association
between the HER-2 breast tumours and nuclear
p21WAF1/CIP1 further implies the ability of HER-2 to mislo-
calise p21WAF1/CIP1. Nuclear p21WAF1/CIP1 is required to
preferentially inhibit cyclin/CDK complexes to ensure DNA
repair and growth suppression of transformed cells. This
process is determined by a carboxyterminal nuclear locali-
sation signal, while mechanisms underlying nuclear export
of p21WAF1/CIP1 remain to be determined. In vitro, active
phosphorylated Akt binds p21WAF1/CIP1 and phosphory-
lates threonine 145 in the nuclear localisation signal to
produce cytoplasmic p21WAF1/CIP1 [21]. In a preliminary
series of five breast cancers, immunohistochemical detec-
tion of phosphorylated Akt was associated with
p21WAF1/CIP1 in both the nucleus and the cytoplasm, sug-
gesting an association with HER-2 activation [21]. This
implies that the relationship between HER-2 and the sub-
cellular localisation of p21WAF1/CIP1 is not exclusive in vitro
and in vivo, but reflects a preferential cytoplasmic localisa-
tion of p21WAF1/CIP1.
Further in vivo studies are required to establish the signifi-
cance of phosphorylated Akt in relation to HER-2 and sub-
cellular localisation of p21WAF1/CIP1, with future
possibilities that immunodetection of phosphorylated
p21WAF1/CIP1 may imply activation of this pathway. Clinical
relevance of HER-2-expressing tumours with cytoplasmic
p21WAF1/CIP1 is emphasised by the independent prognos-
tic significance of both parameters. Prognostic signifi-
cance of cytoplasmic p21WAF1/CIP1 at 5 years retains its
predictive potential for OS and RFS at 9 years. The com-
bined evaluation of cytoplasmic p21WAF1/CIP1 and HER-2
positively did not increase prognostic significance in this
study, due to limited patient numbers in the respective
subsets. As previously reported, nuclear p21WAF1/CIP1
expression was generally low and provided no prognostic
information [17,33,35]. Future studies will be required to
address what are the best markers.
The biological implications of cytoplasmic p21WAF1/CIP1
with respect to the ability to assemble and inhibit
cyclin/CDK complexes and to bind apoptosis signal-regu-
lating kinase 1 require further investigation. Studies in cell
culture suggest a loss of p53 and growth suppressor
function, with inhibition of apoptosis. Subcellular localisa-
tion of p21WAF1/CIP1 may have relevance underlying mech-
anisms of HER-2 drug resistance, with the potential for
cytoplasmic p21WAF1/CIP1-expressing breast tumours to
have increased chemo-resistance or hormone resistance.
Small patient numbers precluded a separate analysis of
treatment relapses in cytoplasmic p21WAF1/CIP1-express-
ing tumours. The potential to define and modify this
pathway through Herceptin inhibition of HER-2 or through
Iressa inhibition of HER-1 could influence downstream
targets of the pathways such as Akt and p21WAF1/CIP1
[38]. The ability of HER-2 to dysregulate p21WAF1/CIP1, a
key target of p53, is highly relevant in the context of p53
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Figure 3
Relationship between HER-2 and prognosis in 67 patients using the
log-rank test. (a) Overall survival curves according to HER-2 status,
classified as negative or positive according to Materials and methods.
(b) Relapse-free survival curves according to HER-2 expression.
Significant P values are indicated in bold.
(a) Relationship between HER-2 and overall survival
(b) Relationship between HER-2 and relapse-free survival
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 P = 0.006wild-type cancers, in which growth suppression and apop-
tosis may be inhibited through mislocalisation of
p21WAF1/CIP1.
Conclusion
These presented findings indicate that HER-2 expression
may influence tumour outcome through a mechanism reg-
ulating the subcellular localisation of p21WAF1/CIP1 to
produce a cytoplasmic distribution resulting in a loss of its
tumour suppressor functions. Cytoplasmic p21WAF1/CIP1
predicts poor prognostic tumours and may have a role in
HER-2-mediated drug resistance, with the potential for
future therapeutic manipulation by Herceptin. Cytoplasmic
p21WAF1/CIP1 may conceivably be a surrogate marker for
HER-2 signalling in vivo to classify clinical subgroups of
patients most likely to benefit from Herceptin, such that
Herceptin inhibition of the pathway could relocate
p21WAF1/CIP1 to the nucleus. A cytoplasmic to nuclear
relocalisation of p21WAF1/CIP1 could be a useful biological
endpoint to analyse the potential efficacy of Herceptin.
Other growth factor pathways involving insulin have
recently been implicated in Herceptin resistance, suggest-
ing biological modifications of the Herceptin response
[20,39]. Increasingly, there is a rationale for identifying
biological markers of drug responsiveness.
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